Personal information

No personal information available

Activities

Collapse all

Employment (2)

Medical University of Vienna: Vienna, AT

2018-11-01 to present | Chair/Professor of Neurology (Neurology)
Employment
Source: Self-asserted source
Thomas Berger

Medical University of Innsbruck: Innsbruck, AT

1995-07-01 to 2018-10-31 | Vice-Chair, Associated Professor (Neurology)
Employment
Source: Self-asserted source
Thomas Berger

Education and qualifications (5)

UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik: Hall in Tirol, AT

2003-10-01 to 2005-03-04 | MSc (Health Economics)
Education
Source: Self-asserted source
Thomas Berger

University of Innsbruck: Innsbruck, AT

1995-07-01 to 1998-09-30 | specialist in neurology and psychiatry (Neurology)
Education
Source: Self-asserted source
Thomas Berger

University of Vienna: Vienna, AT

1993-04-01 to 1995-06-30 | Resident (Neurology)
Education
Source: Self-asserted source
Thomas Berger

University of Vienna: Vienna, AT

1992-01-01 to 1993-03-30 | Resident (Neurological Institute)
Education
Source: Self-asserted source
Thomas Berger

University of Vienna: Vienna, AT

1982-10-01 to 1991-05-23 | MD
Education
Source: Self-asserted source
Thomas Berger

Works (50 of 303)

Items per page:
Page 1 of 7

Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short Version

International Journal of Environmental Research and Public Health
2022-01 | Journal article | Author
DOI: 10.3390/ijerph19020902
Contributors: Patrick Altmann; Dominik Ivkic; Markus Ponleitner; Fritz Leutmezer; Ulrike Willinger; Michaela Schmoeger; Thomas Berger; Gabriel Bsteh; Henriette Löffler-Stastka
Source: check_circle
Multidisciplinary Digital Publishing Institute

Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study

Archives of physiotherapy
2018 | Journal article
Source: Self-asserted source
Thomas Berger

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Therapeutic advances in neurological disorders
2018 | Journal article
Source: Self-asserted source
Thomas Berger

New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases

Multiple sclerosis and related disorders
2018 | Journal article
Source: Self-asserted source
Thomas Berger

Progressive multifocal leukoencephalopathy: Are you aware of it?

2018 | Other
Source: Self-asserted source
Thomas Berger

Real-life clinical use of natalizumab and fingolimod in Austria

Acta Neurologica Scandinavica
2018 | Journal article
Source: Self-asserted source
Thomas Berger

Smoking is not associated with higher prevalence of JC virus in MS patients

European Journal of Clinical Microbiology & Infectious Diseases
2018 | Journal article
Source: Self-asserted source
Thomas Berger

Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts

CNS drugs
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Biomarkers in the evolution of multiple sclerosis

Neurodegenerative disease management
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Cerebrospinal fluid B cells and disease progression in multiple sclerosis-A longitudinal prospective study

PloS one
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Change of olfactory function as a marker of inflammatory activity and disability progression in MS

Multiple Sclerosis Journal
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice--The PeRiCoMS-Study I

Journal of the neurological sciences
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Discontinuation of disease-modifying therapies in multiple sclerosis--Clinical outcome and prognostic factors

Multiple Sclerosis Journal
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Early intervention in multiple sclerosis: how can we maximise patient prospects?

2017 | Other
Source: Self-asserted source
Thomas Berger

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical Measures and Patient-reported Outcomes in Newly Diagnosed and Other Early Relapsing-Remitting Multiple Sclerosis Patients: Subgroup Analysis of PROTEC (P6. 363)

Neurology
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Escalation therapy for multiple sclerosis in Austria: analysis of gender differences in the nationwide registry (P2. 404)

2017 | Other
Source: Self-asserted source
Thomas Berger

Further evidence for the role of olfactory threshold and odor identification as markers of inflammation and neurodegeneration in multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL
2017 | Conference paper
Source: Self-asserted source
Thomas Berger

Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination

Journal of neuroinflammation
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?

Current opinion in neurology
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases

Frontiers in immunology
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Natalizumab-related progressive multifocal leukoencephalopathy in Austria: An observational nationwide study

EUROPEAN JOURNAL OF NEUROLOGY
2017 | Conference paper
Source: Self-asserted source
Thomas Berger

New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria

Multiple Sclerosis Journal
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Olfactory threshold predicts short term relapse activity in relapsing-remitting multiple sclerosis (P2. 347)

2017 | Other
Source: Self-asserted source
Thomas Berger

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study

PloS one
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker for disability progression in multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL
2017 | Conference paper
Source: Self-asserted source
Thomas Berger

Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis

Multiple Sclerosis Journal
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

Neurology
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Real life use of natalizumab and fingolimod-data from the nation-wide Austrian Multiple Sclerosis Treatment Registry

MULTIPLE SCLEROSIS JOURNAL
2017 | Conference paper
Source: Self-asserted source
Thomas Berger

Real-world evidence: Benefits and limitations in multiple sclerosis research

Der Nervenarzt
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Real-world-EvidenzReal-world evidence

Der Nervenarzt
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with maraviroc

Neurology® Neuroimmunology & Neuroinflammation
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging

Acta neuropathologica
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study

PloS one
2017 | Journal article
Source: Self-asserted source
Thomas Berger

The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial

Multiple Sclerosis Journal
2017 | Journal article
Source: Self-asserted source
Thomas Berger

Update: Primäre progrediente Multiple Sklerose (PPMS)//Primary progressive multiple sclerosis (PPMS)--an update

Journal für Neurologie, Neurochirurgie und Psychiatrie
2017 | Journal article
Source: Self-asserted source
Thomas Berger

A Case of Eight-and-a-Half-Syndrome as a Presenting Manifestation of Late Onset Multiple Sclerosis

J Clin Case Rep
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Age-dependent seroprevalence of JCV antibody in children

Neuropediatrics
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Analysis of plasminogen genetic variants in multiple sclerosis patients

G3: Genes, Genomes, Genetics
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders

Journal of neuroinflammation
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Characterizing absolute lymphocyte count profiles in dimethyl fumarate--treated patients with MS Patient management considerations

Neurology: Clinical Practice
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Discontinuation of disease-modifying therapies in relapsing remitting multiple sclerosis-outcome and prognostic factors

MULTIPLE SCLEROSIS JOURNAL
2016 | Conference paper
Source: Self-asserted source
Thomas Berger

Disease Course in Elderly MS Patients (P2. 084)

Neurology
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Effectiveness of delayed-release dimethyl fumarate on clinical disease activity and patient-reported outcomes in patients with relapsing-remitting multiple sclerosis in the real-world setting: a multicentre, open-label study (PROTEC)

MULTIPLE SCLEROSIS JOURNAL
2016 | Conference paper
Source: Self-asserted source
Thomas Berger

Epitope specificity of human MOG antibodies and their pathogenic effect in neuroinflammatory demyelinating diseases

MULTIPLE SCLEROSIS JOURNAL
2016 | Conference paper
Source: Self-asserted source
Thomas Berger

Evaluation of personality, risk and coping in MS patients: a step towards individualized treatment choice

MULTIPLE SCLEROSIS JOURNAL
2016 | Conference paper
Source: Self-asserted source
Thomas Berger

Immunological processes related to cognitive impairment in MS

Acta neurologica Scandinavica
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: Insights from a 10-year observational study

PloS one
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study

Neurology
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies

J Neurol Neurosurg Psychiatry
2016 | Journal article
Source: Self-asserted source
Thomas Berger

Olfactory threshold and odour identification are markers of disease activity in relapsing-onset multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL
2016 | Conference paper
Source: Self-asserted source
Thomas Berger
Items per page:
Page 1 of 7
How many people are using ORCID?